Effect of Quetiapine on negative symptoms and cognition

Study identifier:5077/9007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy of Quetiapine compared to Risperidone on negative symptoms and cognition with regard to underlying neurobiological mechanisms and brain activation.

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

Study drug

Quetiapine fumarate, Risperidone

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2001

Primary Completion Date: -

Study Completion Date: 01 Jan 2003

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca GmbH

+49 4103 708 0

Investigators

Principal Investigator

AstraZeneca Germany Medical Director

AstraZeneca